Effects of Transcutaneous Electrical Nerve Stimulation on Chemotherapy-Induced Peripheral Neuropathy

NACompletedINTERVENTIONAL
Enrollment

151

Participants

Timeline

Start Date

September 10, 2020

Primary Completion Date

October 3, 2022

Study Completion Date

October 3, 2022

Conditions
Chemotherapy-Induced Peripheral Neuropathy
Interventions
DEVICE

Placebo Administration

Wear placebo TENS device

OTHER

Questionnaire Administration

Ancillary studies

DEVICE

Transcutaneous Electrical Nerve Stimulation

Wear active TENS device

Trial Locations (15)

19713

Christiana Health Care System, Newark

29303

Spartanburg Medical Center, Spartanburg

29341

Gibbs Cancer Center-Gaffney, Gaffney

29379

MGC Hematology Oncology-Union, Union

29605

Prisma Health Cancer Institute - Butternut, Greenville

Prisma Health Cancer Institute - Faris, Greenville

29615

Prisma Health Cancer Institute - Eastside, Greenville

29651

Gibbs Cancer Center-Pelham, Greer

33905

Lee Memorial Health System, Fort Myers

49503

Spectrum Health at Butterworth Campus, Grand Rapids

49519

Metro Health Hospital, Wyoming

54301

Saint Vincent Hospital Cancer Center Green Bay, Green Bay

54303

St. Vincent Hospital Cancer Center at St. Mary's, Green Bay

54401

Aspirus, Wausau

62526

Decatur Memorial Hospital, Decatur

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Rochester NCORP Research Base

OTHER

NCT04367480 - Effects of Transcutaneous Electrical Nerve Stimulation on Chemotherapy-Induced Peripheral Neuropathy | Biotech Hunter | Biotech Hunter